PMID- 20644086
OWN - NLM
STAT- MEDLINE
DCOM- 20100906
LR  - 20181201
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 28
IP  - 24
DP  - 2010 Aug 20
TI  - Single-agent arsenic trioxide in the treatment of newly diagnosed acute 
      promyelocytic leukemia: long-term follow-up data.
PG  - 3866-71
LID - 10.1200/JCO.2010.28.5031 [doi]
AB  - PURPOSE We previously reported our results with a single-agent arsenic trioxide 
      (ATO) -based regimen in newly diagnosed cases of acute promyelocytic leukemia 
      (APL). The concern remained about the long-term outcome of this well-tolerated 
      regimen. We report our long-term follow-up data on the same cohort. PATIENTS AND 
      METHODS From January 1998 to December 2004, 72 patients with PML/RARalpha+ APL 
      were enrolled. All patients were treated with a single-agent ATO regimen. Results 
      Overall 62 (86.1%) achieved a hematologic remission (complete remission). After 
      the initial report, an additional seven patients have relapsed for a total of 13 
      relapses. There were no additional toxicities to report on follow-up. At a median 
      follow-up 60 months, the 5-year Kaplan-Meier estimate (+/- SE) of event-free 
      survival, disease-free survival, and overall survival (OS) was 69% +/- 5.5%, 80% 
      +/- 5.2%, and 74.2% +/- 5.2%, respectively. The OS in the good risk group as 
      defined by us remains 100% over this period. CONCLUSION Single-agent ATO as used 
      in this study in the management of newly diagnosed cases of APL is safe and is 
      associated with durable responses. Results in the low-risk group are comparable 
      to that reported with conventional therapy while additional interventions would 
      probably be required in high-risk cases.
FAU - Mathews, Vikram
AU  - Mathews V
AD  - Department of Haematology, Christian Medical College and Hospital, Vellore 
      632004, India; vikram@cmcvellore.ac.in.
FAU - George, Biju
AU  - George B
FAU - Chendamarai, Ezhilarasi
AU  - Chendamarai E
FAU - Lakshmi, Kavitha M
AU  - Lakshmi KM
FAU - Desire, Salamun
AU  - Desire S
FAU - Balasubramanian, Poonkuzhali
AU  - Balasubramanian P
FAU - Viswabandya, Auro
AU  - Viswabandya A
FAU - Thirugnanam, Rajashekar
AU  - Thirugnanam R
FAU - Abraham, Aby
AU  - Abraham A
FAU - Shaji, Ramachandran Velayudhan
AU  - Shaji RV
FAU - Srivastava, Alok
AU  - Srivastava A
FAU - Chandy, Mammen
AU  - Chandy M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20100719
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Arsenicals)
RN  - 0 (Oxides)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Arsenic Trioxide
MH  - Arsenicals/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Hair/metabolism
MH  - Humans
MH  - Infusions, Intravenous
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Promyelocytic, Acute/*diagnosis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Nails/metabolism
MH  - Oxides/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Recurrence
MH  - Remission Induction
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2010/07/21 06:00
MHDA- 2010/09/08 06:00
CRDT- 2010/07/21 06:00
PHST- 2010/07/21 06:00 [entrez]
PHST- 2010/07/21 06:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
AID - JCO.2010.28.5031 [pii]
AID - 10.1200/JCO.2010.28.5031 [doi]
PST - ppublish
SO  - J Clin Oncol. 2010 Aug 20;28(24):3866-71. doi: 10.1200/JCO.2010.28.5031. Epub 
      2010 Jul 19.